---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012057"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:40:28.424616+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech Q2 net loss $13.3M; pauses preferred dividend; two PDUFA dates in Q4 2024

## Summary
- Q2 2024 net revenue $14.9M (dermatology) vs $17.4M Q2 2023; net loss attributable to common $13.3M ($0.73/sh) vs $26.9M ($3.65/sh).
- Cash and equivalents $76.2M at June 30, down from $80.9M at Dec 31, 2023; $38.2M attributable to Fortress/private subs.
- Board paused Series A Preferred Stock (9.375%) dividends indefinitely, deferring ~$0.7M/month; new Oaktree loan $35M (up to $50M) repaid prior $50M, net paydown $15M.
- FDA PDUFA goal dates: DFD-29 for rosacea Nov 4, 2024; cosibelimab for cSCC Dec 28, 2024 – potential approvals in Q4.
- Subsidiary Urica transferred dotinurad rights to Crystalys for 35% equity and 3% royalty; clinical trials ongoing for AJ201 (SBMA) and Triplex (CMV).

## SEC filing metadata
- accession: 0001558370-24-012057
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837024012057/0001558370-24-012057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837024012057/fbio-20240813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012057
- JSON: https://secwatch.observer/filing/0001558370-24-012057.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.